Sarepta Therapeutics: Fourth Quarter Earnings Overview

Sarepta Therapeutics Reports Fourth Quarter Financial Results

Sarepta Therapeutics Inc., headquartered in Cambridge, Massachusetts, announced a net loss of $412.2 million for the fourth quarter.

According to the company, this equates to a loss of $3.93 per share. When excluding expenses related to stock options and other one-time items, the adjusted loss was $3.58 per share.

These figures fell short of analyst expectations. A consensus of seven analysts polled by Zacks Investment Research had anticipated a loss of only $0.71 per share.

Despite the larger-than-expected loss, Sarepta reported quarterly revenue of $442.9 million, surpassing the $408.5 million average forecast from nine analysts surveyed by Zacks.

For the entire year, Sarepta recorded a total loss of $713.4 million, or $7.13 per share, with annual revenue reaching $2.2 billion.